Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US

Goldstein, Stanley; Eftekhari, Sanaz; Mitchell, Lynda; Winders, Tonya; Kaufman, Leslie; Dudas, D.; Paknis, Brandee; Kavati, Abhishek; Delwart, V.; Sofen, Howard

doi:10.2340/00015555-3282

Cited by 10 publications

(23 citation statements)

References 15 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 A clinical report describing the patient experience of having CSU divided the patient journey into 4 stages – Crisis, Searching for Answers, Diagnosis, and Disease Management . 5 Patients in that study described confusion, anxiety, and stress related to diagnosis. Economic impacts were also described, both with direct healthcare costs associated with treatment of CSU, and indirect costs such as days taken off work, recurrent healthcare utilization, and patient presentation to multiple subspecialists in the search for answers.…”

Section: Introductionmentioning

confidence: 94%

Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Rubeiz,

Asero,

Betschel

et al. 2024

World Allergy Organization Journal

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 94%

Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Rubeiz,

Asero,

Betschel

et al. 2024

World Allergy Organization Journal

View full text Add to dashboard Cite

“…Overall, patients provide a very negative perspective of living with CSU. A non-interventional qualitative study found that patients with CSU commonly experienced anxiety, frustration, helplessness, and powerlessness, and reported feelings of loss of normalcy and identity, social stigmatization, shame, and distress [ 45 ].…”

Section: What Is Csu?mentioning

confidence: 99%

“…Furthermore, CSU is often underdiagnosed. For example, a self-report survey ( N = 1037) found that patients suffered from urticaria symptoms for around 3 years before diagnosis [ 48 ], and time to diagnosis is highly variable—even a small study ( N = 25) found that time to diagnosis ranged from 1 week to 15 years [ 45 ]. Diagnosis is also complicated by the presence/absence of angioedema, which is often underreported [ 12 ].…”

Section: What Is Csu?mentioning

confidence: 99%

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Casale,

Gimenez-Arnau,

Bernstein

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.

show abstract

“…The prevalence of chronic urticaria around the world is estimated to be in the range of approximately 0.1% to 1.4%, and its prevalence appears to be increasing [2,3]. CSU patients often experience numerous distressing symptoms, including sleep disturbances, fatigue, and psychological distress, leading to a profound reduction in their quality of life [3][4][5][6] and a substantial burden for health care systems [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials

Xiao

Xue

Shi

et al. 2023

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background Standard doses of second-generation H1-antihistamines (sgAHs) as first-line treatment are not always effective in treating chronic spontaneous urticaria (CSU), and hence an increase in the dose of sgAHs is recommended. However, literature evaluating the efficacy and safety of this treatment remains inconclusive, highlighting the need for a systematic review and meta-analysis. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of high-dose sgAHs compared with standard-dose sgAHs in treating CSU. Methods A systematic literature search of double-blind, randomized controlled trials (RCT) utilizing multiple doses of sgAHs was performed by searching the electronic databases Medline, Embase, PsycInfo, Cochrane databases, and Web of Science. Bibliographies were also manually searched. The Cochrane Risk of Bias Tool for assessing risk of bias was used to assess the quality of randomized controlled trials (RCTs). Two reviewers screened studies, extracted data, and evaluated the risk of bias independently. The response rate, the number of adverse events, somnolence, and withdrawal due to adverse events were extracted from each article. The data were combined and analyzed to quantify the safety and efficacy of the treatment. RevMan (V5.3) software was used for data synthesis. Results A total of 13 studies were identified, seven of which met the eligibility criteria for the meta-analysis. Our pooled meta-analyses showed that high-dose sgAHs was associated with a significantly higher response rate than standard-dose (RR 1.13, 95% CI 1.02 to 1.26; P = 0.02). Conversely, high doses of sgAHs were associated with significantly higher somnolence rates than standard dose (RD 0.05, 95% CI 0.01 to 0.09; P = 0.02). There was no significant difference in adverse events or withdrawal due to adverse events between standard- and high-dose treatments. Conclusions Our analyses showed that a high dose of sgAHs (up to two times the standard dose) might be more effective than a standard dose in CSU treatment. High-dose and standard-dose sgAHs showed similar adverse events, except for somnolence, where incidence was found to be dose-dependent in some studies. However, given the limited number of studies, our meta-analysis results should be interpreted with caution.

show abstract

Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US

Cited by 10 publications

References 15 publications

Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials

Contact Info

Product

Resources

About